Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingxu Da

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Peerj|November 25, 2025
DHCR7: from sterol biosynthesis to oncogenic role in colorectal cancerChuan Zhou, Jia Wang, Han He, et al.
Biochemical Genetics|May 27, 2023
Construction of a Cuproptosis-Related Gene Signature for Predicting Prognosis in Gastric CancerYongli Hu, Yan Du, Zhisheng Qiu, et al.
Discover Oncology|February 13, 2025
Acetyltransferase NAT10 promotes gastric cancer progression by regulating the Wnt/β-catenin signaling pathway and enhances chemotherapy resistanceYawen Chen, Jian Yang, Yadan Du, et al.
The Lancet. Oncology|May 11, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trialJian Zhou, Li Bai, Jia Luo, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Peerj|November 25, 2025
DHCR7: from sterol biosynthesis to oncogenic role in colorectal cancerChuan Zhou, Jia Wang, Han He, et al.
Biochemical Genetics|May 27, 2023
Construction of a Cuproptosis-Related Gene Signature for Predicting Prognosis in Gastric CancerYongli Hu, Yan Du, Zhisheng Qiu, et al.
Discover Oncology|February 13, 2025
Acetyltransferase NAT10 promotes gastric cancer progression by regulating the Wnt/β-catenin signaling pathway and enhances chemotherapy resistanceYawen Chen, Jian Yang, Yadan Du, et al.
The Lancet. Oncology|May 11, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trialJian Zhou, Li Bai, Jia Luo, et al.
Pageof 8